Salient Pharmaceuticals
	Developer of drugs for the treatment of multiple inflammatory gastrointestinal conditions. The company develops a proprietary compound intended for use in treating severe diarrhea associated with chemotherapy, chronic conditions, infectious diseases and other drug therapies.
	['', 'drug compound', ' ', 'gastrointestinal disease', ' ', 'radiation therapy', ' ', 'gastrointestinal treatment', '']
IDEC Pharmaceuticals
	Developer of products for the treatment of cancer and autoimmune diseases. The company was founded with the intent of developing and commercializing monoclonal antibodies. The company looks to find patient specific approaches in treating non-Hodgkin\'s lymphoma.
	['', 'cancer and autoimmune disease', ' ', 'treating lymphoma', ' ', 'patient specific', ' ', 'monoclonal antibody', '']
Gloucester Pharmaceuticals
	Developer of cancer therapeutics. The company develops romidepsin, a histone deacetylase inhibitor and oncology drug candidate for T-cell lymphomas, as well as for the treatment of hematologic malignancies. It also develops treatments for hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma.
	['', 'cancer therapy', ' ', 'hematological cancer treatment', ' ', 'cancer drug', '']
Affimed Therapeutics
	Developer of unique TandAb antibody therapeutics for cancer and inflammatory diseases. The company offers anticancer drug candidates, including AFM13, a bispecific and tetravalent human antibody to treat Hodgkin Lymphoma, AFM11 and AFM15 for the treatment of Non-Hodgkin Lymphoma and autoimmune diseases.
	['', 'inflammatory diseases', ' antibody Lymphoma']
Cabrellis Pharmaceuticals
	Developer of therapies for the treatment of cancer. The company\'s product includes synthetic anthracycline drug for small cell and nonsmall cell lung cancers in Japan. It also has drug commercialization rights in North America and Europe.
	['', 'cancer treatment', ' ', 'lung cancer treatment', ' ', 'drug commercialization', '']
BioInvent
	Developer of antibody-based drug therapies for the treatment of cancer. The company has a pipeline of three proprietary antibodies focused on treatment for multiple myeloma, non-Hodgkin lymphoma and medulloblastoma.
	['', 'antibody drugs', ' ', 'drug developer', ' ', 'multiple myeloma', ' ', 'non-Hodgkin lymphoma', '']
Automated Cell
	Developer of antibody therapeutic antibodies for the treatment of oncology and immune disease. The company is focused on the development of monoclonal antibody therapeutics for the treatment of cancer.
	['', 'antibody therapeutic', ' ', 'therapeutic treatment', ' ', 'oncology disease', ' ', 'immune disease', ' ', 'monoclonal antibody', '']
